Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11696770 | 0.89 | IDO1 (0.51) | IDO1ADRA1AHTR6RETHTR2A | |
| SCHEMBL78935 | 0.87 | IDO1 (0.44) | IDO1ADRA1ACYP11B2HTR6PDPK1 | |
| SCHEMBL10500854 | 0.84 | HTR6 (0.50) | IDO1ADRA1ACYP11B2HTR6PDPK1 | |
| SCHEMBL133896 | 0.80 | HTR2A (0.49) | IDO1ADRA1ACYP11B2PDPK1SIGMAR1 | |
| SCHEMBL14283849 | 0.78 | DRD1 (0.47) | ADRA1A | |
| SCHEMBL10492671 | 0.78 | IDO1 (0.40) | IDO1ADRA1ACYP11B2HTR6PDPK1 | |
| SCHEMBL10492532 | 0.78 | HTR6 (0.41) | IDO1ADRA1ACYP11B2HTR6PDPK1 | |
| SCHEMBL9614919 | 0.77 | HTR6 (0.54) | IDO1ADRA1ACYP11B2HTR6SIGMAR1 | |
| SCHEMBL8849605 | 0.76 | DDB1 (0.53) | IDO1ADRA1ACYP11B2PDPK1SIGMAR1 | |
| SCHEMBL5710152 | 0.76 | PIN1 (0.51) | IDO1ADRA1ACYP11B2PDPK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0143075-B1 | PROCESS FOR THE PREPARATION OF N-GLYCIDYL COMPOUNDS | CIBA-GEIGY AG (CH) | 1987-11-19 | — | — | EP | claimed |
| EP-0099338-B1 | EPOXY RESIN SYSTEMS MODIFIED WITH THERMOPLASTIC RESINS | CIBA-GEIGY AG (CH) | 1986-05-14 | — | — | EP | claimed |
| US-4540769-A | NITRATE, PERCHLORATE, ALPHA-HALO CARBOXYLATE OR SULFONATE | CIBA-GEIGY CORPORATION (US) | 1985-09-10 | — | — | US | claimed |
| EP-0143075-A1 | Process for the preparation of N-glycidyl compounds | CIBA-GEIGY AG (CH) | 1985-05-29 | — | — | EP | claimed |
| US-8076495-B2 | Aromatic N-glycidylamines by catalysis of an aromatic aminehydrogen and epichlorohydrin using a lanthanum nitrate as a catalyst dissolved in propylene carbonate, then dehydrochlorinating | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100179114-A1 | S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents | BRIDGE PHARMA, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7718674-B2 | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine | BRIDGE PHARMA, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080221342-A1 | Process | HUNTSMAN ADVANCED MATERIALS AMERICANS INC. (US) | 2008-09-11 | — | — | US | disclosed |
| CN-100400525-C | Process for the preparation of n-glycidylamines | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1656363-B1 | PROCESS FOR THE PREPARATION OF N-GLYCIDYLAMINES | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2007-10-10 | — | — | EP | disclosed |
| CN-1812976-A | Process for the preparation of n-glycidylamines | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-1656363-A2 | PROCESS FOR THE PREPARATION OF N-GLYCIDYLAMINES | Huntsman Advanced Materials (Switzerland) GmbH (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20060079559-A1 | S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | BRIDGE PHARMA, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006036936-A2 | THE S-ISOMER OF 2-{2-[N-(2-INDANYL)-N-PHENYLAMINO]ETHYL}PIPERIDINE AND OTHER DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005003109-A2 | PROCESS FOR THE PREPARATION OF N-GLYCIDYLAMINES | HUNTSMAN ADVANCED MATERIALS (SWITZERLAND) GMBH (CH) | 2005-01-13 | — | — | WO | disclosed |
| EP-0143075-B1 | PROCESS FOR THE PREPARATION OF N-GLYCIDYL COMPOUNDS | CIBA-GEIGY AG (CH) | 1987-11-19 | — | — | EP | disclosed |
| US-4540769-A | NITRATE, PERCHLORATE, ALPHA-HALO CARBOXYLATE OR SULFONATE | CIBA-GEIGY CORPORATION (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0143075-A1 | Process for the preparation of N-glycidyl compounds | CIBA-GEIGY AG (CH) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179114-A1 | S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents | TRPA1, OPRL1, OPRM1 | IDO1 445/4885ADRA1A 42/4885CYP11B2 1217/4885 |
| US-20080221342-A1 | Process | PAH, TET2, PAM | IDO1 151/4885ADRA1A 702/4885CYP11B2 36/4885 |
| US-20060079559-A1 | S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | OPRL1, TRPA1, OPRM1 | IDO1 129/4885ADRA1A 35/4885CYP11B2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.